Altus rated at buy by Merrill

Altus Pharmaceuticals Inc. was rated by Merrill Lynch analyst Tom McGahren at a buy rating ahead of the company's deadline to report its third-quarter 2006 results. During the call, the analyst will be looking for progress toward resolving the manufacturing glitches that were reported in July for Altus' two lead product candidates, ALTU-135 for the treatment of pancreatic insufficiency, and ALTU-238, a once-weekly injection for growth hormone deficiency. Shares of the Cambridge, Mass.-based biopharmaceutical company were up 21 cents, or 1.23%, at $17.27. (Nasdaq: ALTU)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.